{"id":107410,"date":"2026-08-20T12:00:35","date_gmt":"2026-08-20T12:00:35","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/107410\/"},"modified":"2026-08-20T12:00:35","modified_gmt":"2026-08-20T12:00:35","slug":"astrazeneca-halts-key-lung-cancer-trial-but-shares-barely-flinch","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/107410\/","title":{"rendered":"AstraZeneca Halts Key Lung-Cancer Trial–But Shares Barely Flinch"},"content":{"rendered":"\n

This article first appeared on GuruFocus<\/a>. <\/p>\n

AstraZeneca (NYSE:AZN<\/a>), one of the world’s largest pharmaceutical companies with a major focus on oncology, ended<\/a> its Phase III eVOLVE-Lung02 trial after an independent committee concluded that volrustomig combined with chemotherapy was unlikely to outperform existing treatment options in improving progression-free or overall survival. The study covered 895 patients with metastatic non-small-cell lung cancer across 25 countries, while U.S.-listed shares slipped 0.2% to $156.20. <\/p>\n

The failed trial creates a hole in volrustomig’s future sales opportunity, but it is not a knockout blow for AstraZeneca’s broader growth story. According to Reuters<\/a>, the lung-cancer indication represented roughly 20% of the drug’s projected peak-sales potential. With AstraZeneca previously targeting more than $5 billion in peak sales for volrustomig, the setback could remove around $1 billion of potential revenue. The company is still moving forward with other volrustomig studies in cancers including cervical cancer, head-and-neck cancer and mesothelioma, with no new safety concerns reported. <\/p>\n

Investors appear to view this as a speed bump rather than a broken investment thesis. AstraZeneca offset the disappointment with positive results from other late-stage oncology programs, including advances involving Tagrisso and Enhertu combinations. The bigger question is execution: AstraZeneca has built its valuation around a powerful pipeline and a target of reaching $80 billion in revenue by 2030. Every failed trial makes that target harder to achieve and raises the importance of future drug launches. <\/p>\n

\"AstraZeneca<\/a> AstraZeneca Halts Key Lung-Cancer Trial–But Shares Barely Flinch \u00b7 us.finance.gurufocus <\/p>\n

The valuation picture remains interesting. According to the GF Value chart, AstraZeneca traded at $156.30 versus a GF Value estimate of $179.72, putting the stock about 13% below its estimated intrinsic value. The market is clearly demanding proof from AstraZeneca’s pipeline, but the discount suggests investors may already be pricing in some execution risk. For long-term investors, the key debate is whether today’s uncertainty creates an opportunity before the company’s next wave of oncology growth arrives. <\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), one of the world’s largest pharmaceutical companies with a major…\n","protected":false},"author":2,"featured_media":41713,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,35816,44586,21122],"class_list":["post-107410","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-failed-trial","tag-sales-opportunity","tag-treatment-options"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117127730064312014","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/107410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=107410"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/107410\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/41713"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=107410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=107410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=107410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}